U.S. markets closed

BioXcel Therapeutics, Inc. (BTAI)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
29.89-0.05 (-0.17%)
At close: 4:00PM EDT
29.90 +0.01 (+0.03%)
After hours: 07:00PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Williams %R

Williams %R

Previous Close29.94
Bid29.00 x 1400
Ask30.30 x 1400
Day's Range29.67 - 30.27
52 Week Range23.07 - 67.74
Avg. Volume264,345
Market Cap835.993M
Beta (5Y Monthly)1.05
PE Ratio (TTM)N/A
EPS (TTM)-4.12
Earnings DateNov 10, 2021 - Nov 15, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est92.55
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value

Subscribe to Yahoo Finance Plus to view Fair Value for BTAI

Learn more
View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • BioXcel Therapeutics, Inc.
    Market Digest: CNI, NDAQ, BK, GILD, ISRG, MKTX, NFLX, SWXAs Earnings Roll in, the Economy Rolls on
    Fair Value
    Economic Moat
    4 days agoArgus Research
View more
  • Motley Fool

    This High-Risk, High-Reward Stock Might Double Your Money

    Chasing short-term gains is usually not the best strategy in the stock market. Investing in solid companies and holding their shares for a long time is still the best way to grow your capital. However, some companies with a promising future can provide explosive short-term gains too.

  • GlobeNewswire

    BioXcel Therapeutics Announces Expansion of Phase 2 Trial of BXCL701 in De Novo and Treatment-Emergent Small-Cell Neuroendocrine Prostate Cancer

    Initial findings from Phase 1b/2 trial of BXCL701 in combination with KEYTRUDA met efficacy threshold to support expansion of existing cohort of de novo and treatment-emergent Small-Cell Neuroendocrine Prostate Cancer (SCNC) High unmet medical need with no FDA approved therapies for patients presenting with SCNC Data from the trial, including the expansion cohort, anticipated by Q1 2022 NEW HAVEN, Conn., Oct. 18, 2021 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a clinical-stag

  • Motley Fool

    Why BioXcel Therapeutics Stock Is Sinking Today

    What happened Shares of BioXcel Therapeutics (NASDAQ: BTAI) were sinking 15.2% as of 11:25 a.m. EDT on Thursday. The decline came after the company's regulatory filing to the Securities and Exchange Commission revealed that chief commercial officer William P.